

# Welcome to California COVID-19 Vaccination Program Friday Provider Office Hours

Friday, June 24, 2022




**Vaccinate ALL 58**

Together we can end the pandemic.

# Provider Office Hours Q&A

**During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.**



# Housekeeping

## Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

## Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at:  
<https://eziz.org/covid/education/>



If you have post-webinar questions, please email [leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov)

# Agenda: Friday, June 24, 2022

No.	Item	Speaker	Time (AM)
1	Welcome, Announcements, & Poll	Leslie Amani (Moderator)	9:00 – 9:05
2	Clinical Update	Caterina Liu, M.D. (CDPH)	9:05 – 9:20
3	Vaccine Administration Data	Elizabeth Reosti (CDPH)	9:20 – 9:25
4	CAIR2: COVID-19 Vaccine Updates	Michael Powell (CDPH)	9:25 – 9:30
Q&A			9:30 – 9:35
5	Storage & Handling	Kate McHugh (CDPH)	9:35 – 9:40
6	Vaccine Management	Eric Norton (My Turn) and Daniel Conway (myCAvax)	9:40 – 9:50
7	Wrap Up & Resources	Leslie Amani (Moderator)	9:50 – 10:00
Q&A			



# Announcements

Leslie Amani, CDPH

# Job Aid: Preparing for Infant/Toddler Vaccinations

## Preparing for Infant/Toddler Vaccinations

Whenever new vaccine products are introduced into your practice's supply, ensure staff are properly trained on what's new and reinforce the storage and handling basics staff already know. This guide addresses training issues and setup required to support new pediatric vaccine products.

### #1. Review Clinical, Safety, and Efficacy Talking Points

We'll share findings from the clinical trials once data are available. In the meantime, [review clinical talking points for parents](#) and start talking to families about COVID-19 vaccines now!

### #2. Complete the COVID-19 Product Training

CDC's training for any new vaccine products will be posted [here](#) once released by CDC. In the meantime, review FDA's EUA Fact Sheets for each product you'll administer.

To ensure everyone is proficient with any new products in your inventory, CDC requires that everyone storing, handling, administering, or managing COVID-19 vaccines complete the [COVID-19 Vaccine Product Training](#).

CDC training is broken down into separate *Preparation & Administration* and *Storage & Handling* summaries so staff and clinicians can review the training appropriate to their roles and print them for reference.

Bookmark the [COVID-19 Vaccine Product Guide](#) as a quick reference.

### #3. Review Timing for Doses by Age

Ensure staff know how to identify which vaccine is for which age group. [This chart](#) includes two schedules (routine and for moderately and severely immunocompromised) for primary and booster doses.

California COVID-19 Vaccination Program

IMM-1432 (6/17/22)

### Product Updates

CDC and the California Department of Public Health are updating job aids and communications for the following product authorizations:

- Pfizer-BioNTech COVID-19 boosters for children 5-11Y ([recommended](#))
- Pfizer-BioNTech COVID-19 primary vaccine series for 6M-4Y ([Fact Sheet](#))
- Moderna COVID-19 primary vaccine series doses for 12Y+, boosters for 18Y+ ([Fact Sheet updated](#))
- Moderna COVID-19 primary vaccine series for 6M-5Y ([Fact Sheet](#))
- Moderna COVID-19 primary vaccine series for 6-11Y ([Fact Sheet](#))

COVID Call Center will keep sites posted as new pediatric products or boosters are authorized by FDA and recommended by the Advisory Committee on Immunization Practices (ACIP), CDC, and Western States Scientific Safety Review Workgroup (WSSSRW).

## Includes:

- Safety and Efficacy
- Product Training
- Timing for Doses
- Vaccine Organization
- Preparing Staff
- Links to Resources

# Coming Soon: COVID-19 Vaccine Product Training\*

See highlighted links to CDC product summary sheets, which summarize EUA fact sheets.

## Training includes COVID-19 Vaccine

- Preparation & Administration
- Contraindications and Precautions
- Reporting Doses & Adverse Events
- Storage & Handling

### COVID-19 Vaccine Product Training

This training shows staff how to prepare, administer, store, and handle COVID-19 vaccine products and report adverse events to VAERS. To prepare in advance of initial vaccine shipments, print and review summary sheets—**only for products your location will be ordering**. Review times vary by learner role & technical experience.

Pfizer-BioNtech	Location Coordinator	Vaccinator	Provider
<ul style="list-style-type: none"><li>• Vaccine Preparation &amp; Administration Ages 6M-4Y   Ages 5-11   Ages 12+ (PDF)</li><li>• Mixing Diluent &amp; Vaccine (PDF)</li><li>• Storage &amp; Handling: Ages 6M-4Y   Ages 5-11   Ages 12+ (PDF)</li></ul>	✓	✓	✓
<ul style="list-style-type: none"><li>• Delivery Checklist (PDF)</li></ul>	✓	-	-

Moderna	Location Coordinator	Vaccinator	Provider
<ul style="list-style-type: none"><li>• Vaccine Preparation &amp; Administration &amp; video Ages 6M-5Y   Ages 18+ (PDF)</li><li>• Storage &amp; Handling: Ages 6M-5Y   Ages 18+ (PDF)</li></ul>	✓	✓	✓

NEW

# Infant/Toddler COVID-19 Vaccine Preparation and Administration Summary

6 Months Through 5 Years of Age  
**Moderna COVID-19 Vaccine**  
Vaccine Preparation and Administration Summary

**General Information**

Vaccine: Moderna: 6 months through 5 years of age (dark blue cap and label with a magenta border) **Use the correct formulation based on the age of the recipient**

Multidose vial: 10 doses per vial.

Dosage: 0.25mL.

**Age Indications**

6 months through 5 years of age

**Schedule for Primary Series**

- For an up-to-date vaccination schedule for primary doses and an additional dose (for moderately or severely immunocompromised children) see <https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-older.pdf>

**Prepare and Administer the Vaccine**

**Assess recipient status:**

- Screen for contraindications and precautions.
- Review vaccination history.
- Review medical considerations.

**Follow aseptic technique.** Perform hand hygiene before vaccine preparation, between patients, when changing gloves (if worn), and any time hands become soiled.<sup>1</sup>

**Remove the vaccine from the storage unit. Check the vial label to ensure it is the correct formulation based on the age of the recipient. The vial for children 6 months to 5 years of age has a dark blue cap and label with a magenta border.**

**Vaccine must be thawed before using.** If removing the vial from the refrigerator, let it stand at room temperature for 15 minutes.

**Unpunctured vials:** Check the expiration date. Never use expired vaccine. Note time the vaccine vial was first punctured. Vaccine should be given within 12 hours after the first puncture.

**Punctured vials:** Check when the vial was first punctured before preparing/administering vaccine. Vials and any unused vaccine should be discarded after 12 hours and NOT administered.

**Administration**

Intramuscular injection. For children:

- 6 months through 2 years: Vastus lateralis muscle in the anterolateral thigh<sup>2</sup>
- 3 through 5 years: Deltoid muscle<sup>3</sup>

COVID-19 vaccines may be coadministered with other vaccines, including simultaneous administration.

**Thawing Frozen Vaccine**

- Frozen vaccine must be thawed before using.
- Thaw frozen vaccine in the refrigerator (2°C and 8°C (36°F and 46°F) or at room temperature (8°C to 25°C (46°F to 77°F). See vaccine's fact sheet for detailed information.

With the vial upright, gently swirl the vaccine. **Do NOT shake.** If the vial is shaken, contact the manufacturer. Note: Gently swirl the vaccine before withdrawing subsequent doses.

Examine the vaccine. It should be white to off-white in color and may contain white or translucent particles. Do not use if liquid contains other particulate matter or is discolored.

Using a new, sterile alcohol prep pad, cleanse the stopper of the multidose vaccine vial.

Choose the correct equipment, including the correct needle size. Use a new, sterile needle and syringe for each injection.

Ensure the needle and syringe are secured tightly together to prevent the vaccine from inadvertently leaking during preparation and administration.

06/20/2022 CS221571-A 1

6 Months Through 4 Years of Age  
**Pfizer-BioNTech COVID-19 Vaccine**  
Vaccine Preparation and Administration Summary

**General Information**

Vaccine: Pfizer-BioNTech: 6 months through 4 years of age (maroon cap and maroon bordered label) **Use the correct formulation based on the age of the recipient**

Diluent: 2.2 mL of 0.9% sodium chloride (normal saline, preservative-free) Use a new vial every time.

Multidose vial: 10 doses per vial

Dosage: 0.2 mL

**Prepare the vaccine using a NEW vial of diluent EVERY TIME. Discard the diluent vial and remaining diluent after mixing the vaccine.**

**Age Indications**

6 months through 4 years of age

**Vaccination Schedule**

- For an up-to-date vaccination schedule for Pfizer-BioNTech COVID-19 Vaccine for infants and young children see [www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-older.pdf](https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-older.pdf)

**Prepare the Vaccine**

Follow aseptic technique. Perform hand hygiene before vaccine preparation, between patients, when changing gloves (if worn), and any time hands become soiled.<sup>1</sup>

**Remove vaccine from the storage unit. Check the vial label to ensure it is the correct formulation based on the age of the recipient. The vial for children 6 months through 4 years of age has a maroon cap and maroon border on the label. Allow vaccine to come to room temperature. Vials can be held at room temperature at room temperature for up to 12 hours before mixing.**

**Before mixing, check the:**

- Age indications on the label
- Expiration date of the vaccine and diluent
- Any beyond-use dates/times

**NEVER** use expired vaccine or diluent. **NEVER** use vaccine after the beyond-use date or times.

With the vaccine at room temperature, gently invert vial 10 times. **Do not shake the vial.** If the vial is shaken, contact the manufacturer. The vaccine is white to off-white in color and may contain opaque particles. Do not use if liquid is discolored.

**Administration**

Intramuscular injection:

- 6 months through 2 years: Vastus lateralis muscle in the anterolateral thigh.<sup>2</sup>
- 2 through 4 years: Deltoid muscle in the upper arm.<sup>3</sup>

COVID-19 vaccines may be coadministered with other vaccines, including simultaneous administration.

**Thawing Frozen Vaccine**

- Vaccine stored at ultra-cold temperatures must be thawed before use.
- Thaw vaccine in the refrigerator or at room temperature:
  - Unpunctured vials may be stored in the refrigerator for up to 10 weeks.
  - Unpunctured vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 12 hours prior to mixing (including thaw time).
- Amount of time needed to thaw vaccine varies based on temperature and number of vials.
- Do NOT** refreeze thawed vaccine.
- Use CDC's beyond-use date labels to track storage time at refrigerated temperatures.

Using a new, sterile alcohol prep pad for each vial, wipe off the stoppers of the diluent and vaccine vials. Using a 21-gauge (or narrower) needle, **withdraw 2.2 mL** of 0.9% sodium chloride (normal saline, preservative-free) into a mixing syringe. Discard diluent vial and any remaining diluent every time. **Do NOT** use bacteriostatic normal saline or other diluents to mix the vaccine.

Inject 2.2 mL 0.9% sodium chloride (normal saline, preservative-free) diluent into the vaccine vial.

Using the mixing syringe, remove 2.2 mL of air from the vaccine vial to equalize the pressure in the vaccine vial.

Gently invert the vial containing vaccine and diluent 10 times. The vaccine will be off-white in color. Do not use if discolored or contains particulate matter. **Do not shake.** If the vial is shaken, contact the manufacturer.

Note the date and time the vaccine was mixed on the vial.

Keep mixed vaccine between 2°C and 25°C (36°F to 77°F) for up to 12 hours. **Discard any unused vaccine after 12 hours.** Do not return to ultra-cold freezer storage.

06/20/2022 CS221571-A 1



Vaccinate  
ALL 58

Moderna Infant/Toddler Preparation & Administration Summary Pfizer Infant/Toddler Preparation & Administration Summary



# Job Aid: Vaccine Administration Checklist

### Vaccine Administration Checklist

California COVID-19 Vaccination Program

Use this guidance to help ensure your patients receive sufficient protection after vaccination and to minimize revaccination efforts due to administration errors. Refer to CDC's [Interim Clinical Considerations](#) for additional clinical guidance and exceptional circumstances. Ensure check-in staff and vaccinators are properly trained on [COVID-19 vaccine timing by age](#); ensure vaccinators are properly [trained to prepare vaccine products](#) your site will administer—paying extra attention to dilution of Pfizer COVID-19 vaccine products.

0	Screen recipients carefully and schedule appointments based on eligibility and age at date of vaccination.	Check-In Staff
	<ul style="list-style-type: none"><li>COVID-19 vaccine dosages are based on age—not size or weight.</li><li>Vaccine products may have 2-dose or 3-dose primary series. Refer to <a href="#">COVID-19 Vaccine Timing by Age</a> for age indicators, number/timing of primary and booster doses, recommendations for immunocompromised.</li><li><b>For subsequent doses in primary series:</b> Check My Turn, CAIR, or your EHR to confirm the vaccine product your patient previously received AND timing of the next dose; administration at an incorrect interval may require revaccination. Determine if <a href="#">extended dosing interval</a> for Pfizer/Moderna 2<sup>nd</sup> dose is appropriate.</li><li><b>4-Day grace period:</b> Primary series and booster doses administered up to 4 days before the minimum interval, known as the 4-day grace period, are considered valid.</li><li><b>Interchangeability of COVID-19 vaccine products:</b> In general, the same mRNA vaccine product should be used for all doses in the primary series. See <a href="#">Interim Clinical Considerations</a> for exceptions.</li><li><b>Transitioning from a younger to older age group:</b> People should receive the recommended age-appropriate vaccine dosage based on their age on the day of vaccination.</li></ul>	
1	Carefully check the vaccine vial label against the prescribed vaccine in My Turn or your EHR.	Vaccinators
	<p>Administering the wrong formulation may result in a lower-than-authorized dosage and insufficient protection.</p> <ul style="list-style-type: none"><li>For COVID-19 vaccines, use vial cap color to help distinguish products. Refer to <a href="#">COVID-19 Vaccine Product Guide</a> for cap colors and age indicators by product. (Early shipments of Pfizer 6M-4Y do not correctly state the age indicators. Please refer to the <a href="#">Pfizer Provider Letter</a>.)</li></ul>	
2	Always check expiration date before preparation and administration.	Vaccinators
	<p>Administration of expired vaccine may require revaccination (see <a href="#">CDC revaccination guidance</a>).</p> <ul style="list-style-type: none"><li>See <a href="#">COVID-19 Vaccine Product Guide</a> or <a href="#">EUA Fact Sheets</a> to determine expiration date by vaccine.</li><li>Your vaccine coordinator may have written updated expiration dates on product or outer cartons.</li></ul>	
3	Always check beyond-use limits before preparation and administration.	Vaccinators
	<p>Administration of vaccine past beyond-use limits may require revaccination. See <a href="#">COVID-19 Vaccine Product Guide</a> or <a href="#">EUA Fact Sheets</a> for limits by product.</p>	

California COVID-19 Vaccination Program

IMM-1411 (6/21/22)



## Vaccine Administration Checklist includes:

- Guidance to avoid administration errors
- Links to CDC Interim Clinical Considerations
- Links to training by age
- Link to how to prepare vaccine products
- Screening





# COVID-19 Vaccination Schedules



# LGBTQ+ Outreach and Archived Webinar



[VA58 Information Digest: LGBTQ+ Outreach](#)





[Equality California Training](#)

**Archived:**

**COVID-19 Crucial Conversations Webinar:**

[Archived Slides](#)

[Archived Recording](#)




# Archived Webinars!

## Planning for Infant/Toddler COVID-19 Vaccinations

Dr. Erica Pan, Deputy Director, Center for Infectious Diseases, and CDPH SMEs shared information on "Planning for Infant/Toddler COVID-19 Vaccinations".

[Archived Slides](#)

[Archived Recording](#)



The California Immunization Coalition (CIC) COVID Conversations #11 featuring Dr. Yvonne A. Maldonado, MD, FAAP, FPIDS, FIDSA, Stanford University School of Medicine, and Dr. Robert Schechter, MD, MSC, Chief Immunization Branch, CDPH.

[Archived Slides](#)

[Archived Recording](#)

[California Immunization Coalition Webpage](#)





# Resources: Infant/Toddler & KidsSprint Toolkit & Graphics



**Vaccinate ALL 58**

Encuentra y cuenta

Laberinto

Ayuda a Diego a llegar a su cita de vacunación

**BÚSQUEDA DE PALABRAS**

V	A	C	U	N	A	E	A	M	P	F
I	P	A	E	R	M	E	R	Á	E	H
R	V	E	E	F	I	R	E	S	L	N
U	E	L	L	S	G	F	N	C	O	F
S	R	A	S	O	O	L	A	A	T	A
M	A	Y	R	J	T	N	M	R	A	M
B	N	L	O	U	E	A	R	A	L	I
U	O	S	E	G	U	R	O	I	W	L
S	S	I	T	A	R	G	D	A	S	I
D	I	V	E	R	S	I	Ó	N	S	A
Y	R	E	G	E	T	O	R	P	W	E

SEGURO PLAYA FAMILIA GRATIS  
MÁSCARA VACUNA JUGAR PROTEGER  
SOL SONRISA DIVERSIÓN AMIGO  
VIRUS PELOTA ARENA VERANO

**COLORING SHEET**

Vaccines are safe, free and help protect you from COVID-19

**Vaccinate ALL 58** 1-833-422-4255 | myturn.ca.gov

# Archived: CDC COCA Webinar

CDC/Clinician Outreach and Communication Activity (COCA)  
Webinar

**Topic:** Recommendations for Pfizer-BioNTech and Moderna  
COVID-19 Vaccine Primary Series in Children 6 Months through 5  
Years Old

[Archived Slides](#)

[Archived Recording](#)




# Stay informed!

## Provider Resources on [eziz.org/covid](https://eziz.org/covid)

### Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!

California COVID-19 Vaccination ProgramENHANCED BY Google

Program Updates

Program Enrollment

My Turn Onboarding

Vaccine Management

Vaccine Administration

Reporting Requirements

Archived Communications

Patient Resources

### Provider Support

#### COVID Call Center

Email: [Program Info](#)  
Phone: (833) 502-1245  
Hours: Mon-Fri, 8AM-6PM

Contact us for questions about the program or help with accessing documents.

---

#### myCAvax and My Turn

Email: [myCAvax Technical Support](#), [MyTurn Onboarding](#), [MyTurn Technical Support](#)  
Phone: (833) 502-1245  
Mon-Fri, 7AM-7PM  
Sat-Sun, 8AM-1PM





My Turn Clinic Translation Line:  
(833) 980-3933  
Mon-Fri: 8AM-8PM  
Sun-Sat: 8AM-5PM

---

#### Vaccines

[Manufacturer Contacts](#)

## Updates for Providers

FAQsProvider Office HoursTrainingTraining Calendar

### Alerts:

#### Updated Infant/Toddler Recommendations and Products

- Routine and Small Orders are now open for the Infant/Toddler products. Expect delivery to begin after the wave 2 pre-order delivery window is complete after Wednesday, June 29. [View Pre-Ordering/Delivery Schedule](#)
- Interim Clinical Considerations for Use of COVID-19 Vaccines
- COVID-19 Vaccination Schedule (Timing Guide)
- Guide of COVID-19 Vaccine Products (Updates for Moderna 6-11 years and 12-17 years pending ACIP approval)

#### Planning Resources

- Preparing for Infant/Toddler Vaccinations Job Aid
- Planning for Under 5 Vaccinations Webinar [Recording](#) and [Slides](#)
- [Recommending COVID-19 Vaccination: Clinical Talking Points 6/17/22](#)
- [Requesting COVID-19 Vaccination Staff](#)
- [Expanding Vaccination Capacity](#)

#### Now Enrolling Providers of Pediatric Services

- [Find Information on How to Enroll](#)
- [Dispelling Provider Myths About Joining the California COVID-19 Vaccination Program](#)
- [Welcome VFC Providers | Flyer](#) | [VFC vs. COVID Programs](#)

## Featured Resources

### Tools to Avoid Vaccine Mix-Ups:

- [Vaccine Administration Checklist 6/21/22](#)
- [Preventing Administration Errors 6/21/22](#)
- [Coadministration of COVID-19 Vaccine with Other Vaccines | Tips | Preteens](#)

# COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated weekly: last updated 6/23/2022
- Currently in its 77th iteration!



**Q: How can COVID-19 vaccine Providers submit COVID-19 vaccine reimbursement claims for uninsured individuals?**

A: The U.S. Health Resources & Services Administration (HRSA) stopped accepting COVID-19 vaccine reimbursement claims on April 5, 2022. COVID-19 vaccine Providers who were receiving reimbursement for vaccine administration through HRSA may receive reimbursement through the California Department of Health Care Services (DHCS) [COVID-19 Uninsured Group](#). For guidance on the COVID-19 Uninsured Group, please visit [COVID-19 Vaccine Reimbursement FAQs](#) on the [DHCS COVID-19 Medi-Cal Response page](#).



**Q: If a child moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), which dosage should they receive?**

A: Children should receive the age-appropriate formulation and follow the [vaccine eligibility schedule](#) based on their age on the day of vaccination, regardless of their size or weight. If a child moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine dosage for the older age group for all subsequent doses. For further information, please visit [CDC Interim Clinical Considerations: Transitioning from a younger to older age group](#).

## California COVID-19 Vaccination Program Provider FAQs

For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers. Providers may also visit [California COVID-19 Vaccination Program](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

### Contents

New and Updated FAQs .....	2
Pediatric Providers .....	4
Vaccine Program Management.....	5
Provider Enrollment.....	5
Ordering.....	6
Distribution/Redistribution .....	6
Vaccine Administration .....	7
Additional/Booster Doses .....	9
Vaccine Storage & Handling.....	11
Inventory.....	12
Reporting .....	13
Billing & Reimbursement .....	14
Communication Resources .....	14

[Provider FAQs on EZIZ, Updated Weekly](#)



Vaccinate ALL 58



# COVID-19 Vaccination Program Webinars and Training for Providers

Week of June 27, 2022

Note: Calendar subject to change

	Monday 6/27	Tuesday 6/28	Wednesday 6/29	Thursday 6/30	Friday 7/1
myCAvax	<a href="#">My Turn and myCAvax Office Hours</a> 12:00 pm – 1:00 pm				
Combined Office Hours and Events	<a href="#">Vaccine Order Request with Q&amp;A</a> 10:00 am – 10:30 am  <a href="#">Pfizer BioNTech COVID-19 Vaccine Training &amp; Education*</a> 12:00 pm – 1:00 pm PW: SXpxqFPP265	<a href="#">Pfizer BioNTech COVID-19 Vaccine Training &amp; Education*</a> 12:00 pm – 1:00 pm PW: vXGkbVDv526	<a href="#">Pfizer BioNTech COVID-19 Vaccine Training &amp; Education*</a> 9:00 am – 10:00 am PW: 3JKnTe4GDx5	<a href="#">Pfizer BioNTech COVID-19 Vaccine Training &amp; Education*</a> 9:00 am – 10:00 am PW: MpBZPFCM635	<a href="#">Provider Office Hours</a> 9:00 am – 10:00 am  <a href="#">Pfizer BioNTech COVID-19 Vaccine Training &amp; Education*</a> 12:00 pm – 1:00 pm PW: QMjNKiQX5324
* Pfizer BioNTech COVID-19 Vaccine Training & Education topics vary by day and include the latest information about vaccine storage, handling, preparation, and administration; recent medical updates, healthcare provider resources, and a Q&A session. <b>NOTE: Updated training to include potential Maroon Cap presentation for individuals 6 months through 4 years of age.</b>					
View On Demand	<ul style="list-style-type: none"><li><a href="#">Intro to My Turn Onboarding</a> (v. 1/4/22)</li><li><a href="#">Latest Features in My Turn</a> (*Requires My Turn Login)</li></ul>		<ul style="list-style-type: none"><li><a href="#">Latest Features in myCAvax for Providers</a> (*Requires myCAvax Login)</li><li><a href="#">myCAvax Release Notes for LHJs and CDPH Users</a> (*Requires myCAvax Login)</li><li><a href="#">COVID-19 Crucial Conversations Archived Webinars and Slides</a></li></ul>		<ul style="list-style-type: none"><li><a href="#">Provider 101 Account Enrollment: Section A: Organization Application</a> (v. 10/21/21)</li><li><a href="#">Provider 101 Account Enrollment: Section B: Location Application</a> (v. 10/21/21)</li><li><a href="#">Provider Office Hours and MCE Office Hours Archived Sessions</a></li></ul>

Help

Website: [www.eziz.org/covid](http://www.eziz.org/covid), [FAQs](#)  
General email: [covidcallcenter@cdph.ca.gov](mailto:covidcallcenter@cdph.ca.gov)  
CDPH Provider Call Center: 1-833-502-1245, 8am-6pm

My Turn email: [myturnonboarding@cdph.ca.gov](mailto:myturnonboarding@cdph.ca.gov)  
myCAvax Help Desk Email: [myCAvax.HD@accenture.com](mailto:myCAvax.HD@accenture.com)  
Phone: (833) 502-1245

# Pfizer COVID-19 Vaccine Updates & Trainings

Date & Time (linked)	Password
<a href="#">Friday, June 24 - 12PM</a>	XZqMY8qQV37
<a href="#">Monday, June 27 - 12PM</a>	SXpxqFPP265
<a href="#">Tuesday, June 28 - 12PM</a>	vXGkbVDv526
<a href="#">Wednesday, June 29 - 9AM</a>	3JKnTe4GDx5
<a href="#">Thursday, June 30 - 9AM</a>	MpBZPFCM635
<a href="#">Friday, July 01 - 12PM</a>	QMjNKiQX532
<a href="#">Tuesday, July 05 - 12PM</a>	GBg5xe59Tjp
<p>More sessions listed!</p> <p>NOTE: All times listed here are PDT.</p>	

## Audience:

Providers and immunization staff

## Session Topics Include:

- Potential new vaccine presentation (**Maroon Cap**) for individuals 6 months through 4 years of age\*\* (Starting June 7)
- FDA approvals, authorizations - including recent authorizations
- Extended expiry for **Purple**, **Orange**, and **Gray Cap**
- **Gray Cap**, Comirnaty®
- Use of each vaccine presentation, including storage, handling, preparation, and administration

# Poll: CDPH Appreciates Your Feedback!

How would you rate your overall satisfaction with the services and information provided by the CDPH COVID-19 Vaccine Team to support your work in the CA COVID-19 Vaccination Program?

Examples: Office hours, webinars, call centers, job aids, FAQs, flyers/posters, weekly wrap-ups

- ☐ Very Satisfied
- ☐ Satisfied
- ☐ Neither Satisfied nor Unsatisfied
- ☐ Unsatisfied
- ☐ Very Unsatisfied



# Clinical Update

Caterina Liu, M.D., CDPH



# Moderna & Pfizer Infant/Toddler COVID-19 Vaccines Authorized Under Emergency Use and Recommended by CDC/ACIP

- The Food and Drug Administration's (FDA) Vaccine Related Biologic Products Advisory Committee (VRBPAC) voted to support and the FDA authorized emergency use authorization (EUA) of:
  - Moderna vaccine for 6 through 17 years
  - Moderna vaccine for 6 months through 5 years
  - Pfizer vaccine for 6 months through 4 years
- The CDC's Advisory Committee on Immunization Practices (ACIP) and the Western States Scientific Safety Review Workgroup (WSSSRW) recommend:
  - Moderna vaccine for 6 months through 5 years
  - Pfizer vaccine for 6 months through 4 years
- ACIP voted to recommend the Moderna vaccine for 6-to-17 years on June 23, 2022; WSSSRW recommendation pending.




# Pediatric COVID-19 Vaccine Products

Age	Brand	Dose	Volume per dose	Primary Series
12+ years	Pfizer Moderna	30ug 100ug	0.3ml 0.5ml	2 doses 2 doses
5-11 years 6-11 years	Pfizer Moderna	10ug 50ug	0.2ml 0.5ml	2 doses 2 doses
6-59 months 6-71 months	Pfizer Moderna	3ug 25ug	0.2ml 0.25ml	3 doses 2 doses

# Primary Series Doses for Infant/Toddler:

- **Pfizer** (3 micrograms): 3 doses for ages 6 months to under 5 years



- **Moderna** (25 micrograms): 2 doses for ages 6 months to under 6 years



\*Shorter intervals (3 weeks for Pfizer, 4 weeks for Moderna) are recommended for individuals who are moderately or severely immunocompromised.

# Infant/Toddler COVID-19 Vaccine Products


		Moderna (6M – 5Y)	Pfizer (6M – 4Y)
Dose		25 mcg	3 mcg
Schedule	Dose 1 → 2 Dose 2 → 3	4 weeks (2-dose initial series)	3 weeks 8 weeks
Met primary efficacy outcome: Antibody levels equivalent to levels at older ages associated with protection against severe COVID-19?		Yes	Yes
Preliminary clinical data suggesting at least short-term protection against symptomatic infection?		Yes	Yes (based on few cases)
Effectiveness data yet against severe COVID-19?		No	No
Adverse events		Mostly mild-moderate	Mostly mild-moderate
Any fever v. placebo; <i>fever &gt; 104°F v. placebo</i>		16 v. 7%: 0.2 v. 0%	6 v. 5%: 0.1 v. 0%
Deaths, cases of myocarditis, or new safety concerns identified in trial?		No	No

# Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised


**Pfizer-BioNTech**  
(6 months–  
4 years)



**Pfizer-BioNTech**  
(5–17 years)



**Moderna**  
(6 months–  
5 years)



## AT-A-GLANCE

### COVID-19 Vaccination Schedules

Use the schedules below to determine how many total COVID-19 vaccine doses are recommended based on primary series product, age, and immune status. This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.


#### COVID-19 Vaccination Schedule for Most People

# Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised


**Pfizer-BioNTech**  
(6 months–  
4 years)



**Pfizer-BioNTech**  
(5–11 years)



**Pfizer-BioNTech**  
(12–17 years)




**Moderna**  
(6 months–  
5 years)



Figure 1

## One In Five Parents Of Children Under 5 Want To Vaccinate Their Child For COVID-19 Right Away When Authorized, But Four In Ten Want To Wait And See

Thinking about your child between the ages of...have they received at least one dose of a COVID-19 vaccine, or not? If not, do you think you will get them vaccinated...?



NOTE: Asked of parents or guardians of children under 18. For parents of children under 5, question was worded "Thinking about your child under the age of 5, once there is a COVID-19 vaccine authorized and available for your child's age group, do you think you will...?" See topline for full question wording.

SOURCE: KFF COVID-19 Vaccine Monitor (April 13-26, 2022) • [PNG](#)

[KFF COVID-19  
Vaccine Monitor](#)

# COVID-19 *is* a Childhood Illness

## COVID-19 Impact on Children in California

As of June 8, 2022, reported COVID-19 for ages 0-to-17 years:

- > **1.68 M** cases – 289 K cases (17%) in children under 5 years
- > **10.4 K** hospitalizations
- At least **71** deaths – 25 deaths (35%) in children under 5 years
  - COVID-19 deaths have been the highest among the Latinx population.



# Hospitalizations Among Children

- Children younger than 5 years old were hospitalized **5 times more** during Omicron than Delta.
- Healthy children can also have severe COVID-19.


**6 OUT OF 10**

children under 5 years old who ended up in the hospital did **not** have any underlying health problems.




# Cumulative COVID-19-associated hospitalizations among children and adolescents 6 months–17 years, COVID-NET

March 2020 – March 2022



Source: COVID-NET, [https://gis.cdc.gov/grasp/COVIDNet/COVID19\\_3.html](https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html). May 21, 2022.

# Severity of COVID-19-associated hospitalizations among children and adolescents 6 months–17 years, COVID-NET, December 19, 2021 – March 31, 2022 (Omicron)



BiPaP: bilevel positive pressure, CPAP: continuous positive pressure

Source: COVID-NET data. Accessed May 21, 2022.

# COVID-19 as Cause of Death by Age Group, U.S.

## Cumulative Incidence, March 1, 2020-April 30, 2022

Age in Years	Deaths	Rank of Causes of Death
<1	269	4
1-4	134	5
5-9	134	5
10-14	195	4
15-19	701	4

# Other Pediatric Vaccine Preventable Diseases:

## Hospitalizations per Year Prior to Recommended Vaccines

	Hepatitis A <sup>1</sup>	Varicella <sup>2</sup> (Chickenpox)	Vaccine-type Invasive Pneumococcal Disease <sup>3</sup>	COVID-19 <sup>4</sup>
Age	5–14 years	0–4 years	0–4 years	6 months–4 years
Time period	2005	1993–1995	1998–1999	Year 1: April 2020–March 2021 Year 2: April 2021–March 2022
Hospitalization Burden (Annual rate per 100,000 population)	<1	29-42	40 <sup>5</sup>	Year 1: <b>29.8</b> Year 2: <b>89.3</b>

<sup>1</sup> <https://www.cdc.gov/mmwr/preview/mmwrhtml/ss5603a1.htm>

<sup>2</sup> Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. *Pediatrics*. 2004;114(3):786-792. doi:10.1542/peds.2004-0012

<sup>3</sup> Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. *MMWR Morb Mortal Wkly Rep*. 2005 Sep 16;54(36):893-7. PMID: 16163262.

<sup>4</sup> COVID-NET data, Accessed May 21, 2022.

<sup>5</sup> Vaccine-type invasive pneumococcal disease annual rate for children <5 years in 1998-1999 was 80 per 100,000, of which about 50% were hospitalized.



# Pediatric vaccine preventable diseases: Deaths per year in the United States prior to recommended vaccines

	Hepatitis A <sup>1</sup>	Meningococcal (ACWY) <sup>2</sup>	Varicella <sup>3</sup>	Rubella <sup>4</sup>	Rotavirus <sup>5</sup>	COVID-19 <sup>6</sup>
Age	<20 years	11–18 years	5–9 years	All ages	<5 years	6 months – 4 years
Time period	1990–1995	2000–2004	1990–1994	1966–1968	1985–1991	Jan 2020–May 2022
Average deaths per year	3	8	16	17	20	86

<sup>1</sup>Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 2008; 197:1282–8.

<sup>2</sup>National Notifiable Diseases Surveillance System with additional serogroup and outcome data from Enhanced Meningococcal Disease Surveillance for 2015–2019.

<sup>3</sup>Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. J Infect Dis. 2000;182(2):383–390. doi:10.1086/315714

<sup>4</sup>Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007; 298:2155–63.

<sup>5</sup>Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis. 1996 Sep;174 Suppl 1:S5–11.

<sup>6</sup><https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-Counts-by-Age-in-Years/3apk-4u4f/data>. Accessed May 14, 2022

# Post-COVID conditions in children

- **Post-COVID conditions in children**
  - Appear to be less common in children than in adults
  - A national survey in the UK found **7-8%** of children with COVID-19 reported continued symptoms >12 weeks<sup>1</sup>
  - Can appear after mild to severe infections and after MIS-C
- **Most common symptoms:** Similar to adults and include fatigue, headache, insomnia, trouble concentrating, muscle and joint pain, and cough <sup>2,3</sup>
- **Impact on quality of life:** Limitations of physical activity, feeling distressed about symptoms, mental health challenges, decreased school attendance/participation<sup>2</sup>

<sup>1</sup>Office for National Statistics United Kingdom. (2021) Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Retrieved on September 17, 2021 from Office for National Statistics' website.

<https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021>

<sup>2</sup>Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110(7):2208-2211. doi:10.1111/apa.15870.

<sup>3</sup>Molteni E, Sudre CH, Canas LS, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health 2021; 5: 708–18.

<https://www.thelancet.com/action/showPdf?pii=S2352-4642%2821%2900198-X>




# Myocarditis in young children

## Background rates

- Before the COVID-19 pandemic, peaks in myocarditis hospitalizations seen in infants and adolescents
  - In adolescents, typically **viral** in etiology
  - In infants, many cases can represent cardiomyopathy with **genetic** component

### ■ Children

- Annual incidence 0.8 per 100,000
  - In 15-18yo, 1.8 per 100,000 in 2015-2016
- 66% male
- Median LOS 6.1 days



Vasudeva et al. *American J Cardiology*. 2021.

LOS = Length of hospital stay

Vasudeva et al. Am J Cardiology 2021 <https://www.sciencedirect.com/science/article/pii/S0002914921002617>

Previously presented: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/02-COVID-Oster-508.pdf>

59



## VAERS reporting rates of myocarditis (per 1 million doses administered) after mRNA COVID-19 vaccination, days 0–7 and 8–21 post-vaccination<sup>\*,†</sup>

		0–7 days			8–21 days			0–7 days			8–21 days		
		Males			Males			Females			Females		
Age (yrs)		Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster
Pfizer-BioNTech	5–11	0.2	2.6	0.0	0.6	0.0	0.0	0.2	0.7	0.0	0.2	0.0	0.0
	12–15	5.3	46.4	15.3	1.2	1.2	0.9	0.7	4.1	0.0	0.4	0.2	0.9
	16–17	7.2	75.9	24.1	1.7	3.2	1.3	0.0	7.5	0.0	0.7	0.4	0.0
Pfizer-BioNTech and Moderna	18–24	4.2	38.9	9.9	1.1	2.2	0.4	0.6	4.0	0.6	0.2	0.7	0.0
	25–29	1.8	15.2	4.8	0.4	1.1	0.5	0.4	3.5	2.0	0.2	0.0	0.8
	30–39	1.9	7.5	1.8	0.4	0.8	0.2	0.6	0.9	0.6	0.3	0.2	0.0
	40–49	0.5	3.3	0.4	0.2	0.5	0.0	0.4	1.6	0.6	0.2	0.2	0.0
	50–64	0.5	0.7	0.4	0.2	0.3	0.1	0.6	0.5	0.1	0.2	0.5	0.1
	65+	0.2	0.3	0.6	0.3	0.2	0.1	0.1	0.5	0.1	0.1	0.2	0.1

\* As of May 26, 2022; reports verified to meet case definition by provider interview or medical record review; primary series and 1<sup>st</sup> booster doses only

† An estimated 1–10 cases of myocarditis per 100,000 person years occurs among people in the United States, regardless of vaccination status; adjusted for days 0–7 and 8–21 risk intervals, this estimated background is **0.2 to 2.2 per 1 million person-day 0–7 risk interval** and **0.4 to 3.8 per 1 million person-day 8–21 risk interval** (peach shaded cells indicate that reporting rate exceeded estimated background incidence for the period)

61

## Vaccine-associated myocarditis in young children

- Risk of myocarditis after mRNA COVID-19 vaccination, if any, in young children is unknown
  - No cases occurred during clinical trials (n=7,804 with at least 7 days of follow-up)
- Based on the epidemiology of classic myocarditis and safety monitoring in children ages 5-11 years, myocarditis after mRNA COVID-19 vaccination in young children is anticipated to be rare
  - Underlying epidemiology of myocarditis fundamentally **different** in infants
  - Dose used in young children **lower** than dose used in older children

# Summary of GRADE

## Pfizer COVID-19 vaccine: Children ages 6 months–4 years

Outcome	Importance	Design (# studies)	Findings	Evidence type
<b>Benefits</b>				
1a. Symptomatic lab-confirmed COVID-19 (efficacy)	Critical	RCT (1)	Pfizer-BioNTech COVID-19 vaccine is effective in preventing symptomatic COVID-19; certainty in the estimate was very low	<b>4</b>
1b. Symptomatic lab-confirmed COVID-19 (immunobridging)	Critical	RCT (1)	Pfizer-BioNTech COVID-19 vaccine is effective in preventing symptomatic COVID-19	<b>2</b>
2. Hospitalization due to COVID-19	Important	No studies	Data not available from any studies	<b>ND</b>
3. Multisystem inflammatory syndrome in children (MIS-C)	Important	No studies	Data not available from any studies	<b>ND</b>
4. Asymptomatic SARS-CoV-2 infection	Important	No studies	Data not available from any studies	<b>ND</b>
<b>Harms</b>				
5. Serious adverse events	Critical	RCT (1)	1.0% of participants with SAEs among vaccinated and 1.5% among unvaccinated; certainty in the estimate was very low. 2 SAEs in 1 participant in the vaccine arm were judged to be related to vaccination.	<b>4</b>
6. Reactogenicity	Important	RCT (1)	Severe reactions were slightly more common in vaccinated; any grade ≥3 reaction was reported by 4.3% of vaccinated vs. 3.6% of placebo group	<b>2</b>

Evidence type: 1=high; 2=moderate; 3=low; 4=very low; ND, no data

55

# Summary of GRADE

## Moderna COVID-19 vaccine: Children ages 6 months–5 years

Outcome	Importance	Design (# studies)	Findings	Evidence type
<b>Benefits</b>				
1. Symptomatic lab-confirmed COVID-19	Critical	RCT (1)	Moderna COVID-19 vaccine is effective in preventing symptomatic COVID-19	<b>1</b>
1b. Symptomatic lab-confirmed COVID-19 (immunobridging)	Critical	RCT (1)	Moderna COVID-19 vaccine is effective in preventing symptomatic COVID-19	<b>2</b>
2. Hospitalization due to COVID-19	Important	No studies	Data not available from any studies	<b>ND</b>
3. Multisystem inflammatory syndrome in children (MIS-C)	Important	No studies	Data not available from any studies	<b>ND</b>
4. Asymptomatic SARS-CoV-2 infection	Important	RCT (1)	The vaccine did not demonstrate efficacy in prevention of asymptomatic SARS-CoV-2 infection	<b>3</b>
<b>Harms</b>				
5. Serious adverse events	Critical	RCT (1)	0.5% of participants with SAEs among vaccinated and 0.2% among unvaccinated; certainty in the estimate was very low. Two SAEs which occurred in one participant were judged by the investigator to be related to vaccination.	<b>4</b>
6. Reactogenicity	Important	RCT (1)	Severe reactions were more common in vaccinated; any grade $\geq 3$ reaction was reported by 7.7% of vaccinated vs. 4.1% of placebo group	<b>1</b>

Evidence type: 1=high; 2=moderate; 3=low; 4=very low; ND, no data

40

# Considerations for Extended Interval Between Dose 1 & 2

- Immunocompromised
- High risk for severe disease
- Household member with high risk for severe disease
- High COVID-19 community levels



- Reduced myocarditis risk
- Adolescent and young adult males
- Optimize vaccine effectiveness




# Vaccine Dosage and Interchangeability

- Vaccine Dosage
  - Children should receive the age-appropriate formulation and follow the schedule based on their age **on the day of vaccination**, regardless of their size or weight.
  - If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine dosage for the older age group for all subsequent doses.
- Interchangeability
  - COVID-19 vaccines are not interchangeable.
  - The same mRNA vaccine product should be used for all doses of the primary series.
  - In exceptional situations in which the mRNA vaccine product administered for a previous dose(s) of the primary series cannot be determined or is not available, either age-appropriate available mRNA COVID-19 vaccine product may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 primary vaccination series.




# Children Who Turn from Age 4 to 5 Years Between Any Dose in the Pfizer Primary Series

- **Scenario 1:** A 2-dose primary series using the formulation for people ages 5–11 years (orange cap)




**Scenario 2:** A 3-dose primary series initiated with the formulation for ages 6 months–4 years. Dose 2 and 3 may be with: the formulation for ages 6 months–4 years or the formulation for ages 6–11 years.





# Mixed Series For Children Ages 6 Months-4 Years: 3-Dose Primary Series

Children who receive *different* mRNA products for the first 2 doses of an mRNA COVID-19 vaccine series should receive a third dose of *either* mRNA vaccine 8 weeks after the 2<sup>nd</sup> dose to complete the 3-dose primary series.





# Co-administration

- COVID-19 vaccines may be co-administered with other vaccines on the same day.
- Important to catch-up on routine immunizations. Always check if a patient is up-to-date and, if not, offer catch-up vaccines.
- Integrating COVID-19 vaccination with routine vaccination:
  - Follow best practices to avoid administration errors. See the linked resources below.
  - Use the 15-minute observation after COVID-19 vaccination (30 minutes, if at higher risk for anaphylaxis) to encourage families to **participate in V-safe**, and complete health screening questionnaires and counseling.




COVID-19 vaccine




Other vaccines



## Comforting Restraint Positions




Infants and Toddlers



Older Children

# Giving All the Doses 12 Months and Older

Additional vaccines may be needed. This handout only displays routine vaccines.



Intramuscular (IM) 90° Angle  
Subcutaneous (SC) 45° Angle

- **IM** injections are given in the **anterolateral thigh** (preferred site for 12 mos.-2 yrs.) using a **1" needle**
  - Separate IM injection sites by a minimum of 1"
  - Deltoid is preferred IM site for 3 yrs. and older
    - Anterolateral thigh is an alternative site if deltoid cannot be used
- **SC** injections are given in the upper outer triceps area or thigh using a **5/8" needle** (see • to the left for placement in triceps area)
- Using combination vaccines decreases the number of injections
  - IPV **must** be given IM when given as a combination vaccine (e.g., DTaP-IPV/Hib, DTaP-IPV-HepB)
- Give vaccines likely to cause greater local reaction (e.g., DTaP, PCV) into separate limbs
- Give the most painful injections last (e.g., MMR, PCV)

For additional vaccine administration information see:  
"Administering Vaccines: Dose, Route, Site, and Needle Size"  
at [www.immunize.org/catg.d/p3085.pdf](http://www.immunize.org/catg.d/p3085.pdf)



Revised: June 25, 2019



# Preferred Injection Sites

## Under 3 Years: Vastus Lateralis

### Vaccine Administration: Intramuscular (IM) Injection Children 1 through 2 years of age

**Administer these vaccines by IM injection:**

- Diphtheria, tetanus, and pertussis (DTaP)
- Diphtheria, tetanus, pertussis, polio, and hepatitis B (DTaP-IPV-HepB)
- Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (DTaP-IPV/Hib)
- Diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b and hepatitis B (DTaP-IPV-Hib-HepB)
- Haemophilus influenzae type b
- Hepatitis A (HepA)
- Hepatitis B (HepB)
- Influenza vaccine, inactivated (IIV)
- Inactivated polio vaccine (IPV)\*
- Meningococcal conjugate (MenACWY)
- Pneumococcal conjugate (PCV13)
- Pneumococcal polysaccharide (PPSV23)\*

Notes: Age, recommendations for use, and other indications vary by product. Always review manufacturers' product information as well as the current immunization schedule for children ([www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html](http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html)) before administering vaccine.  
\*May also be administered by subcutaneous injection.

**To ensure vaccines are safe and effective, it's important to prepare and administer them correctly:**

- Follow aseptic technique.
- Use a new, separate needle and syringe for each injection.
- Perform hand hygiene before vaccine preparation, between patients, when changing gloves (if worn), and any time hands become soiled.<sup>1</sup>

<sup>1</sup>Gloves are not required unless the person administering the vaccine is likely to come in contact with potentially infectious body fluids or has open lesions on the hands. If worn, perform hand hygiene and change gloves between patients.

**1. Use the correct syringe and needle.**

- Administer the vaccine using either a 1-mL or 3-mL syringe.
- Use the correct gauge and needle length.<sup>2</sup>
  - 22- to 25-gauge needle
  - 1-inch (25 mm) needle

<sup>2</sup>Use a 5/8- to 1-inch (16 to 25 mm) if using the deltoid muscle. A 5/8-inch needle may be used only if the skin is stretched tightly and the subcutaneous tissue is not bunched.

**2. Identify the injection site.**

- Recommended site: the vastus lateralis muscle in the anterolateral thigh<sup>3</sup>
- Use anatomical landmarks to determine the injection site. The muscle is located on the anterior lateral aspect of the thigh. The middle third of the muscle is used for injections - above the lateral condyle and below the greater trochanter.

<sup>3</sup>The deltoid muscle can be used if the muscle mass is adequate.

**3. Administer the vaccine correctly.**

- Inject the vaccine into the middle and thickest part of the muscle. Insert the needle at a 90-degree angle and inject all the vaccine in the muscle tissue.
- Aspiration (i.e., pulling back on the plunger) is not necessary before injecting the vaccine. No large blood vessels are present at the recommended injection sites, and a process that includes aspiration might be more painful. For more information, see [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html)
- If administering more than one injection in the same limb:
  - Use the vastus lateralis muscle in the anterolateral thigh. It is preferred because of its larger muscle mass.
  - Separate the injection sites by 1 inch if possible.

**For additional information,** go to CDC's clinical resources on vaccine administration: Advisory Committee on Immunization Practices General Best Practice Guidelines for Immunization: Vaccine Administration section at [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html)  
Vaccine administration resource library at [www.cdc.gov/vaccines/hcp/admin/resource-library.html](http://www.cdc.gov/vaccines/hcp/admin/resource-library.html)

02/01/2022 CS 322033-G

**Vastus Lateralis Muscle**

**1 in (25 mm)**

## 3 Years and Over: Deltoid

### Vaccine Administration: Intramuscular (IM) Injection Children 3 through 6 years of age

**Administer these vaccines by IM injection:**

- Diphtheria, tetanus, and pertussis (DTaP)
- Diphtheria, tetanus, pertussis, polio, and hepatitis B (DTaP-IPV)
- Diphtheria, tetanus, pertussis, polio, and hepatitis B (DTaP-IPV-HepB)
- Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (DTaP-IPV/Hib)
- Diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b and hepatitis B (DTaP-IPV-Hib-HepB)
- Haemophilus influenzae type b
- Hepatitis A (HepA)
- Hepatitis B (HepB)
- Influenza vaccine, inactivated (IIV)
- Inactivated polio vaccine (IPV)\*
- Meningococcal conjugate (MenACWY)
- Pneumococcal conjugate (PCV13)
- Pneumococcal polysaccharide (PPSV23)\*

Notes: Age, recommendations for use, and other indications vary by product. Always review manufacturers' product information as well as the current immunization schedule for children ([www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html](http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html)) before administering vaccine.  
\*May also be administered by subcutaneous injection.

**To ensure vaccines are safe and effective, it's important to prepare and administer them correctly:**

- Follow aseptic technique.
- Use a new, separate needle and syringe for each injection.
- Perform hand hygiene before vaccine preparation, between patients, when changing gloves (if worn), and any time hands become soiled.<sup>1</sup>

<sup>1</sup>Gloves are not required unless the person administering the vaccine is likely to come in contact with potentially infectious body fluids or has open lesions on the hands. If worn, perform hand hygiene and change gloves between patients.

**1. Use the correct syringe and needle.**

- Administer the vaccine using either a 1-mL or 3-mL syringe.
- Use the correct gauge and needle length.<sup>2</sup>
  - 22- to 25-gauge needle
  - 5/8- to 1-inch (16 to 25 mm) needle

<sup>2</sup>Use a 1- to 1.25-inch (25-32 mm) needle if administering vaccine in the vastus lateralis muscle in the anterolateral thigh.

**2. Identify the injection site.**

- Preferred site: the deltoid muscle in the upper arm<sup>3</sup>
- Use anatomical landmarks to determine the injection site. The deltoid muscle is a large, rounded, triangular shape. Find the acromion process, which is the bony point at the end of the shoulder. The injection site will be below the bone and above the axillary fold/armpit.

<sup>3</sup>The vastus lateralis muscle in the anterolateral thigh can also be used.

**3. Administer the vaccine correctly.**

- Inject the vaccine into the middle and thickest part of the muscle. Insert the needle at a 90-degree angle and inject all the vaccine in the muscle tissue.
- Aspiration (i.e., pulling back on the plunger) is not necessary before injecting the vaccine. No large blood vessels are present at the recommended injection sites, and a process that includes aspiration might be more painful. For more information, see [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html)
- If administering more than one IM injection:
  - Use the vastus lateralis muscle in the anterolateral thigh for young children. This muscle is preferred for young children because of its larger muscle mass.
  - Separate the injection sites by 1 inch if possible.

**For additional information,** go to CDC's clinical resources on vaccine administration: Advisory Committee on Immunization Practices General Best Practice Guidelines for Immunizations: Vaccine Administration section at [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html)  
Vaccine administration resource library at [www.cdc.gov/vaccines/hcp/admin/resource-library.html](http://www.cdc.gov/vaccines/hcp/admin/resource-library.html)

11/01/2021 CS 322033-H

**Deltoid**

**5/8 in (16mm)** **1 in (25 mm)**

If the skin is stretched tightly and the subcutaneous tissues are not bunched

# COVID-19 Vaccination: Clinical Talking Points

## Recommending COVID-19 Vaccination: Clinical Talking Points for Providers of Pediatric Services



This resource is designed to help you and your staff have effective conversations with families about COVID-19 vaccines, as you are the [most trusted source](#) of medical information for families.

### Begin to discuss COVID-19 vaccination now.

The top reason parents cite for not vaccinating their children is the need for more information. For families who may be hesitant about the COVID-19 vaccine, begin the conversation by asking, "How do you feel about your child getting the COVID-19 vaccine?" The goals of these conversations are to have a cordial discussion, answer questions, understand and acknowledge any fears they express, and provide accurate information.



### Validate parental concerns and answer questions without judgement.

As their child's provider, your guidance is influential. Hearing your opinion that immunization is safe and effective can be reassuring. When parents express hesitation, ask about and acknowledge their concerns. For example, "If I heard those things, I would be scared, too. Let's talk about your concerns." Let parents know that you share their goal of keeping their children safe.

### Give parents accurate information.

Here are common questions and talking points to help parents. Praise parents who ask questions for wanting to know more. Wrap up the conversation by making a recommendation while acknowledging their authority in deciding for their children. For example, "I think getting vaccinated is best for your child. Ultimately, it's your choice. I'm here to guide you and answer your questions."

### Why should my child get the COVID-19 vaccine?

- **It's effective.** The vaccine does not protect against all COVID-19 infection, but [multiple studies](#) have shown it is effective in preventing severe illness and hospitalization, including [against the Omicron variant](#).
  - During the Omicron period, unvaccinated children ages 5-11 were [twice as likely](#) to be hospitalized with COVID-19 than vaccinated children.
  - During the Omicron period, [1 in 5 children](#) hospitalized with COVID-19 required ICU-level care. Vaccination [lowered the risk of critical COVID-19 by 79%](#).
  - [Children with pre-existing conditions](#) are at higher risk for severe COVID-19 outcomes. Vaccination is especially recommended to keep children with chronic conditions and disabilities safe and healthy.

## Providers of Pediatric Services:



- Begin COVID-19 vaccine conversations now
- Listen
- Validate parental concerns
- Answer questions without judgment
- Supply accurate information

## Includes talking points on:

- Myocarditis
- Fertility
- Safety
- And more...



# Job Aid: COVID-19 is a Childhood Illness



# CDC Updated Guidelines and Available Resources

**Information for jurisdictions, clinicians, vaccine providers, and community partners to plan and implement vaccination for children who are eligible:**

- [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) (updated June 19, 2022)
- [Planning COVID-19 Vaccination for Children | CDC](#)
  - [Updated Pediatric COVID-19 Vaccination Operational Planning Guide-Information for Vaccine for Children 6 Months through 4 Years, and Children 6 Months through 5 Years Old \(cdc.gov\)](#)
- [Resources to Promote the COVID-19 Vaccine for Children & Teens | CDC](#)
- [Equity in Childhood COVID-19 Vaccination \(cdc.gov\)](#)
- [CDC COVID Data Tracker](#)
- [Ways Health Departments Can Help Increase COVID-19 Vaccinations | CDC](#)
- [What to Consider When Planning to Operate a COVID-19 Vaccine Clinic](#)
- [How Schools and Early Care and Education \(ECE\) Programs Can Support COVID-19 Vaccination](#)
  - [Hosting Vaccination Clinics: Best Practices for School Districts and Early Care and Education \(ECE\) Programs](#)
  - [Customizable Content for School and Childcare-Located Vaccination Clinics](#)
  - [Considerations for Planning School-Located Vaccination Clinics](#)

**Information for parents and caregivers:**

- [COVID-19 Vaccines for Children and Teens | CDC](#)
- [Frequently Asked Questions about COVID-19 Vaccination in Children | CDC](#)
- [6 Things to Know about COVID-19 Vaccination for Children | CDC](#)
- [V-safe After Vaccination Health Checker | CDC](#)

# FDA VRBPAC & ACIP MEETINGS: JUNE 2022


Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
<b>20</b> Juneteenth Holiday	<b>21</b>	<b>22 ACIP</b>	<b>23 ACIP Moderna EUA for children 6-17 years</b>	<b>24</b>	<b>25</b>
First shipments of vaccine for <5's scheduled to arrive					
<b>27</b>	<b>28 Strain composition of COVID-19 Vaccines</b>	<b>29</b>	<b>30</b>		

# Vaccine Administration Data

Elizabeth Reosti, CDPH

# Vaccine Administration Summary

as of June 20, 2022



**77,108,328**


Total Doses Administered:



**4,283,796** per month, **988,568** per week, **141,224** per day  
**11,768** per hour, **196** per minute, **3** per second

Select Status Category  
Total Eligible Population ▼

- Received Booster
- Booster eligible but not received
- Primary series complete, Booster ineligible
- Primary series incomplete
- Not yet vaccinated
- Statewide comparison, selected metric




Booster/Additional  
Dose Recipients:  
**15,968,856**


# Trends in Vaccine Administration

as of June 20, 2022

Daily Doses Administered: **Statewide**



Weekly Doses Administered: **Statewide** (thousands)





# Trends in Vaccine Administration

as of June 20, 2022


## New Booster Eligibility Driving Demand

- Second boosters among 50+ year-olds
- First boosters among 5-to-11-year-olds

FDA NEWS RELEASE

## Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years

For Immediate Release: May 17, 2022




# 5-to-11-Year-Old Vaccination Trends

as of June 20, 2022

Recent decrease in first doses among 5-to-11-year-olds

Weekly New 5-11 year-old Partially Vaccinated Recipients by VEM: **Statewide**



# Data Summary

as of June 20, 2022

## Latest Metrics

**77.1 Million** doses administered

**247k** doses administered in previous week (-15% pt change)

**5,304** new 5-11-year-old recipients (-2% pt change)

## System Updates

- 4<sup>th</sup> doses included in overall dose admin count, but not currently displayed in immunization status
- Vaccines approved for children 6 months and older (Pfizer and Moderna)

# CAIR2: COVID-19 Vaccine Updates

Michael Powell, CDPH

## Previous (Moderna)

Tradename	CVX
Moderna Spikevax (Red Cap)	207
Moderna (Dark Blue Cap)	221

## New (Moderna)


Tradename	CVX
Moderna (Magenta Border) <6Y	228
Moderna (Purple Border) 6-11Y	221
Moderna Spikevax (Red Cap) 12Y+	207

## New (Pfizer)

Tradename	CVX
Pfizer COVID (Maroon Cap) <5Y	219

# Provider Office Hours Q&A

**During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.**





# Storage & Handling

Kate McHugh, CDPH

# COVID-19 Vaccine Product Guide

## COVID-19 Vaccine Product Guide



**Check vaccine labels before use to avoid mix-ups. Products may look similar.**

Refer to [CDC Product Guide](#) for more information. Details may differ from packaging; [EUA fact sheets](#) supersede info on vials and carton. Note: Pfizer 12+ (purple cap) no longer distributed.

	Pfizer			Moderna			Janssen (J&J)
	Infant/Toddler 6 months–4 years*	Pediatric 5–11 years	Adol/Adult 12+ years	Infant/Toddler 6 months–5 years	6–11 years: primary* 18+ years: booster	12+ years: primary* 18+ years: booster	Adult 18+ years
				 Magenta Border	 Purple Border	 Light Blue Border	
Packaging	Maroon Cap	Orange Cap	Gray Cap	Dark Blue Cap	Dark Blue Cap	Red Cap	Blue Cap
Doses Per Vial	10 doses	10 doses	6 doses	10 doses	5 doses	10–11 doses	5 doses
Carton Size	100 doses	100 doses	60 doses	100 doses	50 doses	100 doses	50 doses
Min. Standard Order	100 doses	100 doses	300 doses	100 doses	100 doses	100 doses	100 doses
Carton NDC #	59267-0078-4	59267-1055-4	59267-1025-4	80777-279-99	80777-275-99	80777-273-99	59676-580-15
CVX	219	218	217	228	221	207	212
<b>Storage Limits Before Puncture:</b> Label vaccine with expiration and use-by dates. Strictly comply with manufacturer guidance.							
ULT (-90°C to -60°C)	Until expiration	Until expiration	Until expiration				
Thermal Shipper							
Freezer				Until expiration (-50°C to -15°C)	Until expiration (-50°C to -15°C)	Until expiration (-50°C to -15°C)	
Refrigerator (2–8°C)	Up to 10 weeks	Up to 10 weeks	Up to 10 weeks	Up to 30 days	Up to 30 days	Up to 30 days	Until expiration
Checking Expiration Dates†	12 months from manufacture date. <a href="#">Check FDA fact sheet.</a>	12 months from manufacture date. <a href="#">Check FDA fact sheet.</a>	12 months from manufacture date. <a href="#">Check FDA fact sheet.</a>	Check product <a href="#">website</a> or QR code	Check product <a href="#">website</a> or QR code	Check product <a href="#">website</a> or QR code	Check product <a href="#">website</a> , QR code, or call 800-565-4008

\* Labels for Pfizer Maroon Cap and Moderna Booster products may not reflect expanded age ranges.  
† Do not dispose of expired vaccine until checking with manufacturers for extended expiration dates.

California COVID-19 Vaccination Program

IMM-1399 (6/23/22)



	Moderna		Janssen (J&J)
	6–11 years: primary 18+ years: booster	12+ years: primary* 18+ years: booster	Adult 18+ years
Do not dilute.	Do not dilute.	Do not dilute	Do not dilute
0.5 mL (50 mcg dose)	0.5 mL (50 mcg dose)	0.5 mL (100 mcg dose)	0.5 mL
0.5 mL (only ages 18+)	0.5 mL (only ages 18+)	0.25 mL* (only ages 18+)	0.5 mL
2 hours (Let vial stand at room temp for 15 min before administering.)	2 hours (Let vial stand at room temp for 15 min before administering.)	2.5 hours (Let vial stand at room temp for 15 minutes before administering.)	If needed immediately, thaw at room temperature
45 minutes at 15° to 25°C (59° to 77°F)	45 minutes at 15° to 25°C (59° to 77°F)	1 hour at 15° to 25°C (59° to 77°F)	Carton: up to 4 hrs Vial: about 1 hour at 25°C (77°F) max
Store up to 24 hours at 8°C to 25°C (46°F to 77°F)	Store up to 24 hours at 8°C to 25°C (46°F to 77°F)	Store up to 24 hours at 8°C to 25°C (46°F to 77°F)	Store up to 12 hours at 9°C to 25°C (47°F to 77°F)
Discard after 12 hours at 2°C to 25°C (36°F to 77°F)	Discard after 12 hours at 2°C to 25°C (36°F to 77°F)	12 hours at 2°C to 25°C (36°F to 77°F) Discard after 20 punctures.	6 hours at 2° to 8°C (36°F to 46°F) or 2 hours at 25°C (77°F) max

IMM-1399 (6/23/22)

NEW

# Infant/Toddler Vaccine Products S&H Summaries

6 Months Through 5 Years of Age  
**Moderna COVID-19 Vaccine**  
Storage and Handling Summary

**Basics**

- Store vaccine in a freezer or refrigerator. See guidance below for each storage unit.
- Each box contains 10 multidose vials.
  - Each multidose vial contains up to 10 doses.
- Each box is approximately 2 inches by 2 inches by 5.4 inches
- Check and record storage unit temperature each workday. See guidance below for each type of temperature monitoring device. Save storage records for 3 years, unless your jurisdiction requires a longer time period.

**Deliveries**

**Vaccine**

- The vaccine will arrive frozen between -50°C and -15°C (-58°F and 5°F).
- Examine the shipment for signs of damage.
- Open the box and remove TagAlert Temperature Monitor from box (placed in the inner box next to vaccine).
- Check the TagAlert temperature monitoring device by pressing the blue "start and stop" button.
  - Left arrow points to a **green checkmark**: The vaccine is ready to use. Store the vaccine at proper temperatures immediately.
  - Right arrow points to a **red X**: The numbers 1 and/or 2 will appear in the display. Store the vaccine at proper temperatures and label **DO NOT USE!** Call the phone number indicated in the instructions or your jurisdiction's immunization program **IMMEDIATELY!**
- The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date:
  - Scan the QR code located on the outer carton, or
  - Go to [www.modernatx.com/covid19vaccine-usa/](https://www.modernatx.com/covid19vaccine-usa/).

**Ancillary Supply Kit**

An ancillary supplies kit will be delivered separately from the vaccine and includes:

- Administration supplies:** Needles, syringes, sterile alcohol prep pads, vaccination record cards, and some PPE.
- Ancillary supply kit(s) support the number of doses ordered.

**Freezer**

Unpunctured, frozen vaccine vials may be stored in the freezer between -50°C and -15°C (-58°F and 5°F).

- Store in the original carton.
- Protect from light.
- Do not store with dry ice or below -50°C (-58°F).
- Do NOT refreeze thawed vaccine.

06/19/2022 00010714 1

**McKesson**

**ALERT: Do not Place on Dry Ice**

**INSTRUCTIONS**

- Remove TagAlert Temperature Monitor from Box (placed in inner box next to vaccine).
- Follow Receiver Instructions on the card.
  - Press and hold the Start & Stop button until the Stop icon appears.
  - Read indicator status to determine if the appropriate temperature was maintained during transit.

Vaccine should be placed in appropriate storage as soon as possible upon receipt.

6 Months Through 4 Years of Age  
**Pfizer-BioNTech COVID-19 Vaccine**  
Storage and Handling Summary

**Basics**

- Store vaccine in an ultra-cold freezer or refrigerator. See guidance below for each storage unit.
- Do NOT store in:
  - The thermal shipping container\*
  - A freezer
- Check and record storage unit temperatures each workday. See guidance below for each type of storage unit. Save storage records for 3 years, unless your jurisdiction requires a longer time period.

**Deliveries**

**Vaccine**

- The vaccine will arrive in a thermal shipping container at ultra-cold temperatures between -90°C and -60°C (-130°F and -76°F) with dry ice. The vial for children 6 months through 4 years of age has a maroon cap and maroon-bordered label.
- Follow the manufacturer's guidance ([www.cvdvaccine-us.com/](https://www.cvdvaccine-us.com/)) for:
  - Unpacking the vaccine
  - Returning the temperature monitoring device
  - Disposing of the thermal shipping container.

**Ancillary Supply Kit**

An ancillary supply kit will be delivered separately from the vaccine and includes:

- Mixing supplies:** Diluent, needles, syringes, and sterile alcohol prep pads
  - Mixing supplies are packaged separately with a green identification label.
  - Do NOT use mixing supplies to administer vaccine.
- Administration supplies:** Needles, syringes, sterile alcohol prep pads, vaccination record cards, and some PPE.
- Ancillary supply kits support the number of doses ordered.

\*Thermal shipping containers delivered to Alaska, Hawaii, and the US-affiliated Pacific Islands may be used as temporary storage. Refer to the manufacturer for more detailed guidance on using the thermal shipping container for storage: <https://www.cvdvaccine-us.com/product-storage-and-dry-ice>

**Ultra-Cold Freezer**

Before mixing, the vaccine may be stored in an ultra-cold freezer between -90°C and -60°C (-130°F and -76°F).

- Store vaccine vials upright in the tray or box.
- Protect from light.
- Vaccine may be stored until the expiration date. Vaccine expires 12 months after the manufacture date.
  - The manufacture date is printed on the vial.
  - Count out 12 months, using the month printed on the vial as month 1.
- The vaccine expires on the last day of the 12th month
- Expired vaccine should NEVER be administered. To prevent this, use CDC's COVID-19 Vaccine Expiration Date Tracking Tool
- As the expiration date approaches, contact the manufacturer to determine if it has been extended. Do not discard vaccine without ensuring the expiration date has passed.

Month 1: Jan 2022 (Printed on vial)

Month 3: March 2022

Month 6: June 2022

Month 9: Sept 2022

Month 12: Dec 2022 Expires Dec 31, 2022

06/18/2022 00001070-6K 1



Vaccinate  
ALL 58

Moderna Infant/Toddler (6mos-5yrs) S&H Summary

Pfizer Infant/Toddler (6mos-4yrs) S&H Summary



# Job Aid: Preventing Administration Errors

## Preventing Administration Errors

California COVID-19 Vaccination Program

Once an error or deviation has occurred, use this guidance to prevent the administration error from occurring again. Refer to CDC's [Interim Clinical Considerations](#) or [Revaccination Guidance](#) for next steps.

An administration error is any preventable event that may cause or lead to improper use of vaccine or patient harm. To reduce errors, complete [COVID-19 vaccine product training](#) and demonstrate competency for products your site will administer. Report errors to [VAERS](#) and [ISMP](#) to help prevent future errors.

Error Type	Guidance to Prevent Administration Errors
Wrong Site or Route	<p><b>Administer COVID-19 vaccines in deltoid muscle (or anterolateral thigh) using IM injection.</b></p> <ul style="list-style-type: none"><li>If multiple vaccines are administered at a single visit, administer each injection in a different injection site. Post this <a href="#">anatomical illustration</a> to help identify recommended injection sites.</li><li>For people ≥11 years, the deltoid muscle can be used for more than one intramuscular injection administered at different sites in the muscle.</li><li>For children (5–10 years), if more than two vaccines are injected in a single limb, the vastus lateralis muscle of the anterolateral thigh is the preferred site because of greater muscle mass.</li><li><b>For 6 months through 2 years:</b> The injection site is the vastus lateralis in the anterolateral thigh.</li><li><b>For 3 years and older:</b> The injection site is the deltoid muscle.</li><li>An IM injection given with too short a needle is functionally a subcutaneous injection; post <a href="#">this reference guide</a> and use clinical judgment to adjust needle length for patient weight and gender.</li><li>COVID-19 vaccines may be administered without regard to timing of other vaccines. If coadministering COVID-19 vaccine with routine vaccines, <a href="#">prepare and organize syringes</a> to ensure products are administered in correct site and route.</li><li>Ask patient to completely expose their shoulder when administering in the deltoid muscle. Ensure vaccinators can locate upper/lower borders of a safe IM injection zone. Incorrect administration into shoulder joint instead of deltoid muscle can trigger inflammation and injury.*</li></ul>
Wrong Age	<p><b>Do not administer vaccine to an unauthorized age group.</b></p> <ul style="list-style-type: none"><li>Select the correct vaccine product based on patient <a href="#">eligibility and age</a> at date of vaccination.</li></ul>
Wrong Formulation	<p><b>Select correct vaccine formulation based on patient age at date of vaccination.</b></p> <ul style="list-style-type: none"><li>COVID-19 vaccine dosages are based on patient age—not size or weight; administering the wrong formulation may result in a lower-than-authorized dosage and insufficient protection.</li><li>Double check vial label; always verify patient birthdate. (Early shipments of Pfizer 6M-4Y do not correctly state the age indicators. Please refer to the <a href="#">Pfizer Provider Letter</a>.)</li><li>Refer to <a href="#">COVID-19 Vaccine Product Guide</a> for cap colors and age indicators by product.</li></ul>
Overdosage	<p><b>Do not administer a higher-than-authorized vaccine injection volume for primary series and additional or booster doses.</b></p> <ul style="list-style-type: none"><li>If too much vaccine is administered, dose may invoke stronger adverse effects; double check <a href="#">injection volume</a> for product &amp; dose before administration. (Report adverse events to <a href="#">VAERS</a>.)</li></ul>

California COVID-19 Vaccination Program

IMM-1410 (6/21/22)

## Preventing Administration Errors includes:

- Revaccination Guidance
- Error Types
- VAERS (Vaccine Adverse Event Reporting System)
- ISMP (Institute for Safe Medication Practices)
- Reporting
- Top 10 Errors Related to COVID-19 Vaccination





# Job Aid: Reporting Inventory to VaccineFinder

**COVID Locating Health**  
POWERED BY Castlight

COVID-19 Vaccines Other Vaccines Public Display Need Help?

[← Back to Inventory](#)

## Add Vaccines to Your Inventory

Any vaccines you add to your inventory will appear automatically in your most recent .csv file as well as on your manual dashboard.

1. Choose vaccines to add (select all that apply):

☐ Select all vaccines

☐ Moderna, COVID-19 Vaccine, 100mcg/0.5mL 10 dose  
(Moderna 12Y+ red cap)

☐ Janssen, COVID-19 Vaccine, 0.5 mL

☐ Pfizer-BioNTech, COVID-19 Vaccine, 10 mcg/0.2 mL, tris-sucrose  
(Pfizer 5-11Y orange cap)

☐ Pfizer-BioNTech, COMIRNATY, 30 mcg/0.3 mL, tris-sucrose  
(Pfizer 16Y+ gray cap)

☐ Pfizer-BioNTech, COVID-19 Vaccine, 30 mcg/0.3mL  
(Pfizer 12Y+ purple cap)

☐ Pfizer-BioNTech, COVID-19 Vaccine, 30 mcg/0.3mL, tris-sucrose  
(Pfizer 12Y+ gray cap)

☐ Pfizer-BioNTech, COVID-19 Vaccine, 3 mcg/0.2 mL, tris-sucrose  
(Pfizer 6M-4Y maroon cap)

☐ Moderna, COVID-19 pediatric vaccine, 25mcg/25 ml  
(Moderna 6M-5Y dark blue cap)

2. Choose locations where you'd like to add your selected vaccines (select all that apply):

☐ Select all locations

☐ Your Clinic Name  
Your address

Begin reporting Infant/Toddler inventory once vaccines arrive, at least weekly on Fridays by close of business.

	Pfizer 6M-4Y (maroon)	Pfizer 5-11Y (orange)	Pfizer 12Y+ (gray)	Pfizer 12Y+ (purple)	Moderna 6M-5Y (dark blue)	Moderna 12Y+ (red)	Janssen (blue)
NDC	59267-0078-4	59267-1055-4	59267-1025-4	59267-1000-2	80777-279-99	80777-273-99	59676-580-15
Max Doses Reported	10	10	6	6	10	10	5

Report these maximum quantities for unpunctured vials.

# What is Happening with Moderna 6-to-11?

- It's coming!
  - Shipments will likely begin late next week or early the week of the 4<sup>th</sup>.
- They are repurposing the Moderna "booster-only" vials for this age group because the concentration is the same as a booster dose.
  - This means the vials will initially arrive mislabeled because they were already manufactured!
  - These vials will have a blue cap and purple border.
- What about Moderna 12-to-17?
  - Moderna 12-to-17 will use the same adult vials (with a red cap) that you already have in inventory



# Moderna 6-to-11 Vial Presentation

- **Blue** cap and **purple** border
- Mislabeled – says booster dose only
- 5 doses per vial
- 0.5mL injection volume
- Same storage conditions as the other Moderna products
  - -50C to –15C for long-term storage
  - 2C to 8C for up to 30 days in the fridge
- Letter explaining the mislabeling




# Links to EUA Fact Sheets and Healthcare Provider Letter

- Moderna Infant/Toddler 6 months-5 years
  - [Provider fact sheet](#)
  - [Recipient/caregiver factsheet](#)
- Pfizer Infant/Toddler 6 months-4 years
  - [Provider fact sheet](#)
  - [Recipient/caregiver fact sheet](#)
  - [Letter to explain mislabeling](#)
- Moderna 6 years-11 years
  - [Provider fact sheet](#)
  - [Recipient/caregiver fact sheet](#)
  - [Letter to explain mislabeling](#)

# Vaccine Management

Eric Norton, My Turn, and Daniel Conway, myCAvax

# Help Desk Chat Virtual Assistant–Launched June 17<sup>th</sup>!



The Help Desk Chat launched a Virtual Assistant for My Turn Clinic and Public as well as myCAvax on **June 17<sup>th</sup>**.

Get help with tasks directly in the chat by clicking on the item.

**My Turn Clinic and myCAvax** users can use Virtual Assistant for the following:

- Password Reset
- User Account Reactivation
- User Account Deactivation

# What's New in My Turn Release 28!



New updates for My Turn Public and Clinic launched on 6/20.



## My Turn Public

### Release Highlights

- ✓ The Pfizer Infant/Toddler 3 dose primary series for children 6 months- 4 years old has been deployed.
- ✓ The Moderna Infant/Toddler 2 dose primary series for children 6 months- 5 years old has been deployed.

## My Turn Clinic

### Release Highlights

- ✓ The Moderna Infant/Toddler 6 months-5-years two dose series has been enabled.
- ✓ The Pfizer Infant/Toddler 6 months-4-years three-dose vaccine series has been enabled.
  - ✓ VA Flow Updates & EUA Links
  - ✓ Update to Dose Fields
  - ✓ Add Vaccine Supply & Inventory
  - ✓ Bulk Walk-In Upload
  - ✓ Clinic Creation Setup
  - ✓ Walk-in flow Update
  - ✓ Vaccine Administrator Flow Update
  - ✓ Single/Bulk Update
  - ✓ Appointment/IIS Tab Filter Update

# Release 28 - Infant/Toddler Updates



In Release 28, **Pfizer Infant/Toddler** (3 doses) and **Moderna Infant/Toddler** (2 doses) were deployed through scheduling, walk-ins, and inline and CSV bulk-upload on **My Turn Public and Clinic**.

Clinic Managers and Vaccine Administrators can now create and update appointments for Infants/Toddlers ages 6 months – 5 years and schedule all doses in the series.



# Moderna Ages 6-to-17 Ordering and My Turn Update



**The FDA amended the Emergency Use Authorization (EUA) to include the Moderna 6-to-11 and 12-to-17 age groups.**


ACIP met yesterday and voted in favor of recommending Moderna 6-to-11 and Moderna 12-to-17. The Western States Scientific Safety Review Workgroup will be meeting soon to review their recommendations as well. My Turn Clinic and Public will be updated soon. myCAvax will also provide additional information about ordering information as we receive it from CDC.

# Infant/Toddler Deliveries This Week!



**Deliveries for Wave 1 and Wave 2 of the Pfizer Infant/Toddler (6 months-4 years, **Maroon Cap**) and Moderna Infant/Toddler (6 months-5 years, **Blue Cap**) are occurring this week!**

Monday	Tuesday	Wednesday	Thursday	Friday
<b>June 20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>
Previously Scheduled Wave 1 Deliveries	Previously Scheduled Wave 2 Deliveries			
<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>1</b>



Monday	Tuesday	Wednesday	Thursday	Friday
<b>June 20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>
Expected Wave 1 Deliveries			Expected Wave 2 Deliveries	
<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>1</b>
Expected Wave 2 Deliveries				

# Ordering for Infant/Toddler Vaccine



You can place Small Orders for the **Pfizer Infant/Toddler** (6 months - 4 years, **Maroon Cap**) through **AmerisourceBergen** (TPR) as of **June 20<sup>th</sup>** (Minimum 30 doses, Maximum 90 doses).



**Routine Ordering:** Now all Infant/Toddler Orders follow the [Order and Distribution Cadence Calendar](#).

# APPENDIX

# What's New on My Turn: Release 28 (06/20)

## My Turn Public

### General Enhancements

- ✓ Pfizer Infant/Toddler rollout for 3 dose primary series for children 6 months-4 years old
- ✓ Moderna Infant/Toddler rollout for 2 dose primary series for children 6 months-5 years old
- ✓ [Testing] Update error messaging for better user experience and accessibility

## My Turn Clinic

### General Enhancements

- ✓ Moderna Infant/Toddler 6 months-5-years two dose series
- ✓ Pfizer Infant/Toddler 6 months-4-years three-dose vaccine rollout
  - ✓ VA Flow Updates & EUA Links
  - ✓ Update to Dose Fields
  - ✓ Add Vaccine Supply & Inventory
  - ✓ Bulk Walk-In Upload
  - ✓ Clinic Creation Setup
  - ✓ Walk-in flow Update
  - ✓ Vaccine Administrator Flow Update
  - ✓ Single/Bulk Update
  - ✓ Appointment/IIS Tab Filter Update
  - ✓ Dashboard Homepage Update

# myCAvax – Known Issues - *Updated 6/20*

## Known Issues

### **Inventory On-Hand Records Not Updating upon Second Save**




- ✓ We are currently investigating an issue in which saving orders as 'Draft' through multi-line ordering and then changing the on-hand inventory data, upon order submission, is not saving the changes made to the on-hand inventory data.

## Workaround/Next Steps

- ✓ Fix: TBD
- ✓ No Workaround for the Time Being



# Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

# myCAvax Release Roadmap

## RECENTLY DEPLOYED

*June 16th (R27.0)*

### Orders

- ✓ LHDs to Move Small Orders to Standard Orders
- ✓ Order Page Layout Changes
- ✓ New order cancelation 'Status Reason' options
- ✓ Update Audit History for Orders/Transfers
- ✓ Add 'Doses Requested' to Standard Order Screen

### Account

- ✓ Storing docusign at the Location Application

### Community

- ✓ Add Knowledge Center article to account page
- ✓ Change Flow Title for Multiple Flows

### Other

- ✓ Auto-Deactivate Licenses
- ✓ Default tab display on opening of records
- ✓ Remaining email templates to Lightning

## IN PROGRESS

*July 14th (R28.0)*

### Orders

- ✓ Order Fulfillment Updates to allow multiple lots and general UI enhancements
- ✓ Allow CDPH and LHD users to update additional details on the Shipment Records such as quantity, product, expiration date, etc.
- ✓ Validate Shipping Hours
- ✓ Set Flags for Temporary Closure on Vaccine Order Review page

### Account

- ✓ Temporary Closure for Location Accounts
- ✓ Add VFC Regions to Accounts
- ✓ Add Calibration Expiration date to Storage Unit List

### Community

- ✓ Update Thermometer Type options
- ✓ Add Data Logger as Shipment Incident Type

### Site Visits

- ✓ Provider Category
- ✓ VFC Assigned Pin

### Other

- ✓ Put LHD Dashboard on LHD Homepage

## UPCOMING

*August 11<sup>th</sup> (R29.0)*

### Orders

- ✓ Draft Order Enhancements

### Account

- ✓ Provider initiated Disenrollment
- ✓ Disenrollment due to inactivity

### Other

- ✓ Start of Contact enhancements to remove duplicate contacts
- ✓ Sharing Rule enhancements for accounts, storage units, etc.

# My Turn Public Product Roadmap

## RECENTLY DEPLOYED

June 20<sup>th</sup> (R27)

### Release 28

- ✓ Pfizer Infant/Toddler rollout for 3 dose primary series for children 6 months-4-years old
- ✓ Moderna Infant/Toddler rollout for 2 dose primary series for children 6 months-5-years old
- ✓ [Testing] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ Continued Analysis – Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

## CURRENT

July 13<sup>th</sup> (R28.4)

### Release 28.4

- ✓ Moderna 6-11 and 12-17 rollout
- ✓ [Testing] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ Continued Analysis – Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

## UPCOMING

July 27<sup>th</sup> (R29)

### Release 29

- ✓ Removing flu – zero out flu vaccine supplies to remove nasal spray and flu shot tags
- ✓ In-home vaccination and transportation page updates to reflect guidance for under 5 patients
- ✓ [Testing] Custom flows for vaccine type
- ✓ [Delivery] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ [Testing] Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

# My Turn Clinic Product Roadmap

## RECENTLY DEPLOYED

*June 20<sup>th</sup> (R28)*

### Release 28

- ✓ Moderna Infant/Toddler 6 month-5-years two dose series
- ✓ Pfizer Infant/Toddler 6 month-4-years three dose series
  - ✓ Dose Fields Update
  - ✓ Add Vaccine Supply & Inventory
  - ✓ Bulk Walk-In Upload
  - ✓ Clinic Creation Setup
  - ✓ Walk-in Flow Update
  - ✓ Vaccine Administrator Flow Update
  - ✓ Single/Bulk Update
  - ✓ Appointment/IIS Tab Filter Update
  - ✓ Dashboard Homepage Update

## CURRENT

*July 13<sup>th</sup> (R28.4)*

### Release 28.4

- ✓ Moderna 6-years-11-years two dose series
- ✓ Moderna 12-years-17-years two dose series
  - ✓ Add Vaccine Supply & Inventory
  - ✓ Bulk Walk-In Upload
  - ✓ Clinic Creation Setup
  - ✓ Walk-in Flow Update
  - ✓ Vaccine Administrator Flow Update
  - ✓ Single/Bulk Update
  - ✓ Appointment/IIS Tab Filter Update
  - ✓ Dashboard Homepage Update

## UPCOMING

*July 27<sup>th</sup> (R29)*

### Release 29

- ✓ [SMS/Email] Opt-out on the Walk-In flow
- ✓ [Vaccine Inventory] Entering Lot Numbers correctly
- ✓ [CAIR2] Concatenate "Cross Street 1" and "Cross Street 2"

# Wrap-up

Leslie Amani, CDPH

# Additional Support

## Type of Support

## Description

Updated 6.6.22



### COVID-19 Provider Call Center

The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical providers in California and their COVID-19 response, specifically addressing questions about State program requirements, enrollment, and vaccine distribution, including the Vaccine Marketplace.


- Email: [covidcallcenter@cdph.ca.gov](mailto:covidcallcenter@cdph.ca.gov)
- Phone: (833) 502-1245, Monday through Friday from 8AM–6PM



### Enrollment Support

For Provider enrollment support, please contact myCAvax Clinic Operations at

- Email: [myCAvaxinfo@cdph.ca.gov](mailto:myCAvaxinfo@cdph.ca.gov)




### myCAvax Help Desk

Dedicated staff provide up-to-date information and technical support on the myCAvax system.

- Email: [myCAvax.HD@Accenture.com](mailto:myCAvax.HD@Accenture.com)
- Phone: (833)-502-1245, option 3, Monday through Friday 8AM–6PM

For training opportunities: <https://eziz.org/covid/education/>




### My Turn Clinic Help Desk

For **onboarding support** (those in the process of onboarding): [myturnonboarding@cdph.ca.gov](mailto:myturnonboarding@cdph.ca.gov)

For **technical support** with My Turn Clinic for COVID-19 and flu vaccines: [MyTurn.Clinic.HD@Accenture.com](mailto:MyTurn.Clinic.HD@Accenture.com) or (833) 502-1245, option 4: Monday through Friday 8AM–6PM

For job aids, demos, and training opportunities: flu at <https://eziz.org/covid/myturn/flu/> and COVID at <https://eziz.org/covid/myturn/>



### Archived Communications

For archived communications from the COVID-19 Provider Call Center about the California COVID-19 Vaccination Program visit

- Website: [EZIZ Archived Communications](#)



# Hear it? Clear It.

If you see or hear of any vaccine-related rumors within the communities you serve, share them with our Trust and Safety team via the CDPH Rumors Inbox.



## Trust and Safety Team

Our shared mission is to reduce COVID-19 vaccine hesitancy and increase vaccination across the State of California.



## How You Can Help

You are critical in our effort to provide Californians accurate and timely information around COVID-19 vaccination.



## Monitor What You See and Hear

Monitor online media and what you hear in your local communities for potential rumors and inaccurate information.

If found, **report** it to **[rumors@cdph.ca.gov](mailto:rumors@cdph.ca.gov)**

[Contact](#)


# Public COVID-19 Call Center

- Phone: (833) 422-4255: M-F 8AM-8PM; S-S 9AM-5PM
- For questions about general COVID questions, including COVID-19 vaccines, scheduling vaccination appointments through My Turn, school-related question, masking, testing, and more.



# Provider Office Hours Q&A

**During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.**



# Thank you!



**Monday**

**My Turn and myCAvax Office Hours**

Next session: Monday, June 27, 12PM

**Friday**

**Provider Office Hours**

Next session: Friday, July 1, 9AM